Ana Jovanović

2.7k total citations
83 papers, 1.0k citations indexed

About

Ana Jovanović is a scholar working on Physiology, Organic Chemistry and Molecular Biology. According to data from OpenAlex, Ana Jovanović has authored 83 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Physiology, 19 papers in Organic Chemistry and 15 papers in Molecular Biology. Recurrent topics in Ana Jovanović's work include Lysosomal Storage Disorders Research (46 papers), Carbohydrate Chemistry and Synthesis (19 papers) and Trypanosoma species research and implications (13 papers). Ana Jovanović is often cited by papers focused on Lysosomal Storage Disorders Research (46 papers), Carbohydrate Chemistry and Synthesis (19 papers) and Trypanosoma species research and implications (13 papers). Ana Jovanović collaborates with scholars based in United Kingdom, Germany and United States. Ana Jovanović's co-authors include Roy Taylor, Aleš Linhart, Dominique P. Germain, Christoph Wanner, João Paulo Oliveira, Alberto Ortíz, Frank Weidemann, Kathy Nicholls, Albina Nowak and Derralynn Hughes and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of the American College of Cardiology and PLoS ONE.

In The Last Decade

Ana Jovanović

79 papers receiving 998 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ana Jovanović United Kingdom 17 744 291 211 186 173 83 1.0k
Ana María Martins Brazil 21 1.2k 1.6× 513 1.8× 251 1.2× 229 1.2× 361 2.1× 101 1.4k
Sema Kalkan Uçar Türkiye 14 203 0.3× 74 0.3× 205 1.0× 142 0.8× 99 0.6× 86 632
Imtiaz A. Samjoo United States 15 364 0.5× 126 0.4× 211 1.0× 127 0.7× 68 0.4× 42 955
Mei‐Chyn Chao Taiwan 16 192 0.3× 104 0.4× 277 1.3× 34 0.2× 78 0.5× 52 804
Wen-Hui Tsai Taiwan 18 238 0.3× 126 0.4× 287 1.4× 31 0.2× 129 0.7× 28 775
Marie De Antonio France 13 203 0.3× 175 0.6× 209 1.0× 21 0.1× 165 1.0× 25 689
Laura Gilliam United States 16 516 0.7× 94 0.3× 708 3.4× 118 0.6× 28 0.2× 51 1.6k
Kyle Scott United States 10 182 0.2× 55 0.2× 491 2.3× 42 0.2× 30 0.2× 21 997
Anna Lehman Canada 20 211 0.3× 54 0.2× 579 2.7× 125 0.7× 43 0.2× 77 1.3k
François Feillet France 15 212 0.3× 49 0.2× 248 1.2× 26 0.1× 97 0.6× 45 685

Countries citing papers authored by Ana Jovanović

Since Specialization
Citations

This map shows the geographic impact of Ana Jovanović's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ana Jovanović with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ana Jovanović more than expected).

Fields of papers citing papers by Ana Jovanović

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ana Jovanović. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ana Jovanović. The network helps show where Ana Jovanović may publish in the future.

Co-authorship network of co-authors of Ana Jovanović

This figure shows the co-authorship network connecting the top 25 collaborators of Ana Jovanović. A scholar is included among the top collaborators of Ana Jovanović based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ana Jovanović. Ana Jovanović is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sharma, Reena, Simon Jones, Robert Wynn, et al.. (2025). Iron metabolism and hematological abnormalities in adult patients affected with mucopolysaccharidoses. Molecular Genetics and Metabolism Reports. 44. 101243–101243.
2.
McCarron, Éamon P, Rajkumar Chinnadurai, Jonathan M. Meyer, et al.. (2025). Real-world clinical outcomes in adult patients with Fabry disease: A 20-year retrospective observational cohort study from a single centre. Molecular Genetics and Metabolism Reports. 43. 101229–101229. 4 indexed citations
3.
Jovanović, Ana, Eve Miller‐Hodges, Obaro Evuarherhe, et al.. (2025). Clinical Efficacy and Real-World Effectiveness of Fabry Disease Treatments: A Systematic Literature Review. Journal of Clinical Medicine. 14(14). 5131–5131. 2 indexed citations
4.
Hughes, Derralynn, Gere Sunder‐Plassmann, Ana Jovanović, et al.. (2024). Renal and multisystem effectiveness of 3.9 years of migalastat in a global real‐world cohort: Results from the followME Fabry Pathfinders registry. Journal of Inherited Metabolic Disease. 48(1). e12771–e12771. 7 indexed citations
5.
Sharma, Reena, et al.. (2024). Retrospective analysis of arginase 1 deficiency progression in adults over 5 years at a single metabolic centre. JIMD Reports. 65(6). 382–391. 1 indexed citations
6.
7.
Black, Nicholas, Josephine H. Naish, Peter Woolfson, et al.. (2023). Disease-specific therapy for the treatment of the cardiovascular manifestations of Fabry disease: a systematic review. Heart. 110(1). 19–26. 6 indexed citations
8.
Watkins, Amy, Maélène Lohézic, David Clark, et al.. (2023). Inflammatory Fabry Cardiomyopathy Demonstrated Using Simultaneous [18F]-FDG PET-CMR. JACC Case Reports. 15. 101863–101863. 1 indexed citations
9.
Vijapurapu, Ravi, Hibba Kurdi, Peter Woolfson, et al.. (2023). Clinical utilisation of implantable loop recorders in adults with Fabry disease—a multi-centre snapshot study. Frontiers in Cardiovascular Medicine. 10. 1323214–1323214. 1 indexed citations
10.
Linhart, Aleš, Gabriela Dostálová, Kathy Nicholls, et al.. (2023). Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study. Orphanet Journal of Rare Diseases. 18(1). 332–332. 24 indexed citations
11.
Bradley, Joshua, Laura Bonnett, Josephine H. Naish, et al.. (2022). Validated Model for Prediction of Adverse Cardiac Outcome in Patients With Fabry Disease. Journal of the American College of Cardiology. 80(10). 982–994. 23 indexed citations
12.
Vijapurapu, Ravi, William Bradlow, Francisco Leyva, et al.. (2022). Cardiac device implantation and device usage in Fabry and hypertrophic cardiomyopathy. Orphanet Journal of Rare Diseases. 17(1). 6–6. 9 indexed citations
13.
Hopkin, Robert J., Gustavo Cabrera, John L. Jefferies, et al.. (2022). Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry Registry. Molecular Genetics and Metabolism. 138(2). 106967–106967. 13 indexed citations
14.
Thomsen, Christer, Edoardo Malfatti, Ana Jovanović, et al.. (2021). Proteomic characterisation of polyglucosan bodies in skeletal muscle in RBCK1 deficiency. Neuropathology and Applied Neurobiology. 48(1). e12761–e12761. 13 indexed citations
15.
Germain, Dominique P., Perry Elliott, Bruno Falissard, et al.. (2019). The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts. Molecular Genetics and Metabolism Reports. 19. 100454–100454. 161 indexed citations
16.
Germain, Dominique P., Eva Brand, Alessandro P. Burlina, et al.. (2018). Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study. Molecular Genetics & Genomic Medicine. 6(4). 492–503. 81 indexed citations
17.
Jovanović, Ana, et al.. (2018). An atypical p.N215S variant of Fabry disease with end-stage renal failure. Molecular Genetics and Metabolism Reports. 15. 43–45. 8 indexed citations
18.
Stępień, Karolina M., Su Han Lum, J. E. Wraith, et al.. (2017). Haematopoietic Stem Cell Transplantation Arrests the Progression of Neurodegenerative Disease in Late-Onset Tay-Sachs Disease. JIMD Reports. 41. 17–23. 14 indexed citations
19.
Mitrović, Veselin, et al.. (2011). Soluble Guanylate Cyclase Modulators in Heart Failure. Current Heart Failure Reports. 8(1). 38–44. 28 indexed citations
20.
Jovanović, Ana, et al.. (2009). The Second-Meal Phenomenon in Type 2 Diabetes. Diabetes Care. 32(7). 1199–1201. 76 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ana María Martins Breakdown of academic impact, for papers by Sema Kalkan Uçar Breakdown of academic impact, for papers by Imtiaz A. Samjoo Breakdown of academic impact, for papers by Mei‐Chyn Chao Breakdown of academic impact, for papers by Wen-Hui Tsai Breakdown of academic impact, for papers by Marie De Antonio Breakdown of academic impact, for papers by Laura Gilliam Breakdown of academic impact, for papers by Kyle Scott Breakdown of academic impact, for papers by Anna Lehman Breakdown of academic impact, for papers by François Feillet
Rankless by CCL
2026